Evolving Evidence in Pediatric Brain Cancer: Spotlight in MAPK InhibitorsLocation: Ballroom D, Tampa Convention Center
Chair: Tabitha Cooney, MD –
Boston, MA
Speakers:Tabitha Cooney, MD – Dana-Farber, Boston, Massachusetts
Jason Fangusaro, MD – Children’s Healthcare of Atlanta, Atlanta, Georgia
Scott Coven, DO, MPH – Riley Children’s Health, Indianapolis, Indiana
Brain cancers are the most common solid tumors of children and include gliomas, meningiomas, and primitive neuroectodermal tumors. The identifi cation of upregulation of the RAS–mitogen-activated protein kinase (RAS/MAPK) pathway as a near universal feature of these tumors has led to the development of targeted therapeutics.
This satellite symposium will bring together 3 clinical experts to highlight evolving applications and considerations for pediatric patients with brain cancer, including the latest information on recent clinical trial data for MAPK inhibitors and strategies to personalize care.
Registration: For more information and to register, please
click here.
Statement: Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity is supported by an educational grant from Day One Biopharmaceuticals, Inc.
Clinical Considerations for Certain Patients With von Hippel-Lindau (VHL) DiseaseLocation: 124 & 125, Tampa Convention Center
Speaker: Rimas Lukas, MD - Northwestern Medicine, Chicago, Illinois
Supported by 
Establishing Patient-Forward Care: A Candid Conversation on Tumor Treating Fields Location: 120 & 121, Tampa Convention Center
Speakers:
Nicholas Blondin, MD – Yale School of Medicine & Smilow Cancer Hospital, New Haven, Connecticut
Nicholas Avgeropolous, MD – UF Health Cancer Center, Gainesville, Florida
Volker Stieber, MD –Wake Forest University School of Medicine & Novant Health Forsyth Medical Center, Winston-Salem, North Carolin
Kellie Kopp, RN, BSN, OCN –Norton Cancer Institute, Louisville, Kentucky
Join us for an unfiltered discussion on the use and integration of Tumor Treating Fields in the clinic, featuring a panel of experts detailing their first-hand experience.
Registration: For more information and to register, please
click here. Pre-registering isn’t required.
Supported by 
TUKYSA® (tucatinib): Clinical Trial DataLocation: 116 & 117, Tampa Convention Center
Speaker: Nikita C. Shah, MD - Orlando Health UF Health Cancer Center, Orlando, Florida
Supported by 
Pediatric Cases of Neurofibromatosis Type 1 (NF1) With Symptomatic, Inoperable Plexiform Neurofibromas (PN) Location: 114 & 115, Tampa Convention Center
Speaker: Gurcharanjeet Kaur, MD – Columbia Neurology, New York City, New York
Alexion invites you to join a dynamic physician-led case-based discussion with a specialist in Neurofibromatosis Type 1 (NF1). Gurcharanjeet Kaur, MD, a nationally recognized specialist in NF1, will present 3 cases of pediatric NF1 patients with symptomatic, inoperable Plexiform Neurofibromas (PN). The presentation will discuss patient diagnosis, treatment, and care.
Dr Kaur is a board-certified child neurologist and a pediatric neuro-oncologist. Her interests include Neurofibromatosis related tumors, cancer related neurotoxicity, and tumor targeted therapy for low grade gliomas. Dr. Kaur remains committed to clinical and pre-clinical research. She has been involved in clinical trials as a site principal investigator and co-investigator. She mentors’ residents, fellows, and medical students interested in the field of child neurology and neuro-oncology.
Registration: Registration information will be posted shortly.
Supported by 
Date: Saturday, November 19, 2022
Time: 12:45PM – 1:15PM
Clinical Case Challenge: Can You Effectively Manage Patients with NF1-Associated Tumors? Location: Ballroom D, Tampa Convention Center
Speakers: Roger J. Packer, MD - Children's National Hospital, Washington, DC
Jaishri Blakeley, MD - Johns Hopkins University School of Medicine, Baltimore, Maryland
Cynthia J. Campen, MD, MScE - Stanford University, Stanford, California
Neurofibromatosis type 1 (NF1) is a complex autosomal dominant disorder caused by germline mutations in the NF1 tumor suppressor gene. NF1-associated tumors present unique challenges and require an individualized approach to patient care. Optimal management of patients as part of a multidisciplinary team involves the adoption of a strategic approach based on current best practices and emerging clinical data. This 90-minute, live symposium will feature 3 expert faculty who will discuss advances surrounding NF1-associated tumors and deliver interactive case presentations addressing NF1-associated tumor management strategies. Key highlights will include an overview of NF1-associated tumors, clinical presentation, and emerging clinical data. The clinical case challenge will focus on diagnostic methods, tailored treatment decision making, management of adverse events, challenges and barriers in practice, and the role of the multidisciplinary team. The presentation will be followed by a panel discussion. Participants will be able to engage in interactive polling throughout the symposium.
Registration: For more information and to register, please
click here.
Supported by Medscape through an independent educational grant from Alexion Pharmaceuticals, Inc.Laser Ablation and the Oncology Patient: New Evidence, What’s Coming, and What You Need to KnowLocation: 124 & 125, Tampa Convention Center
Speakers: John de Groot, MD - University of California San Francisco Health, San Francisco, California
Peter E. Fecci, MD, PhD - Duke Health, Durham, North Carolina
Roy E. Strowd III MD, Med, MS - Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina
Registration: For more information and to register, please
click here.
Supported by 
ONC201 Phase 3 in H3 K27M Diffuse GliomaLocation: 120 & 121, Tampa Convention Center
Speakers:
Allen Melemed, MD - Chimerix, Inc., Durham, North Carolina
Joshua E. Allen, PhD - Chimerix, Inc., Duham, North Carolina
Isabel Arrillaga-Romany, MD, PhD - Mass. General Hospital, Boston, Massachusetts
Timothy Cloughesy, MD – UCLA, Los Angeles, California
Registration: For more information and to register, please
click here.
Supported by 
Molecular Tumor Board: Case Studies Presentation
Location: 124/125, Tampa Convention Center
Speakers:
Kenneth Aldape, MD - National Cancer Institute, Bethesda, Maryland
Farshad Nassiri, MD - University of Toronto, Toronto, Ontario
Gelareh Zadeh, MD, PhD - University of Toronto, Toronto, Ontario
Justin Wang, PhD - University of Toronto, Toronto, Ontario
